BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 05, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ceplene histamine dihydrochloride regulatory update

EpiCept submitted an NDA to FDA for Ceplene histamine dihydrochloride for use in combination with low-dose IL-2 for the remission maintenance and prevention...

Read the full 94 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >